Gastrointestinal tract
Crohn disease
An idiopathic inflammatory bowel disease with transmural, granulomatous inflammation in discontinuous “skip” lesions, most often in the terminal ileum; it forms fissures, fistulas and strictures.
Causes and risk factors
- Idiopathic, with genetic susceptibility: certain HLA types and NOD2 mutations
- TH1 and TH17 immune responses drive the inflammation
- More common in the United States and Western Europe
Gross pathology
- A thickened bowel wall with loss of the mucosal folds and deep fissures.
- Fat creeping over the serosa.
- Discontinuous “skip” lesions; the terminal ileum is the favourite site, but any part of the gut can be involved.
Under the microscope
- Transmural inflammation, from ulcerated mucosa to the serosa.
- Non-caseating granulomas with epithelioid and giant cells, and many lymphocytes.
How it develops
- Inflammation begins in patches, often in the terminal ileum.
- It extends through the full thickness of the wall, with granulomas.
- Serosal involvement causes adhesions and fistulas to neighbouring loops, the skin or the perirectal tissues.
- Fibrosis narrows the bowel (a “string sign” on barium studies); the course relapses over decades.
Complications
- Fistulas (enteroenteric, perirectal) and adhesions
- Strictures
- Malabsorption of vitamin B12 and bile salts (steatorrhoea) with terminal ileal disease
- Extraintestinal manifestations; some increased risk of adenocarcinoma
Investigations
- Ileocolonoscopy with biopsy
- Skip lesions with aphthous and linear ulcers (cobblestoning); biopsies may show non-caseating granulomas.
- MR or CT enterography
- A thickened terminal ileum, strictures and fistulae.
- Blood and stool tests
- Raised CRP, anaemia, low albumin; faecal calprotectin reflects intestinal inflammation.
Drug treatment
- Aminosalicylates (5-ASA): Drugs that release 5-aminosalicylic acid in the bowel, where it acts locally against inflammation; the mainstay for inducing and maintaining remission in mild to moderate ulcerative colitis.
- Thiopurines (azathioprine, mercaptopurine): Immunosuppressive purine antimetabolites that stop lymphocytes proliferating; steroid-sparing maintenance treatment in Crohn disease and ulcerative colitis.
- Systemic corticosteroids (glucocorticoids): Powerful anti-inflammatory and immunosuppressive hormones acting on nuclear receptors: used for flares of inflammatory bowel disease, asthma attacks, brain-tumour oedema and many other conditions, at the price of wide-ranging adverse effects.
- TNF-α inhibitors: Monoclonal antibodies and fusion proteins that neutralise tumour necrosis factor-α, a key inflammatory cytokine; used in moderate to severe Crohn disease, ulcerative colitis, psoriasis and inflammatory arthritis.
- Methotrexate (antifolate): A folic acid antagonist that inhibits dihydrofolate reductase: in high doses a cytotoxic drug for osteosarcoma and leukaemias; in low weekly doses an immunosuppressant for psoriasis, rheumatoid arthritis and Crohn disease.
Drugs to avoid or use with care
- Haematinics: iron, folic acid and vitamin B12 (Use with care): Oral iron can irritate the inflamed bowel; intravenous iron is often used.
Anatomy involved
Connected topics
Written from
- Robbins and Cotran Atlas of Pathology, 3rd ed., Ch. 7, The Gastrointestinal Tract, pp. 203–204, figs 7-85 to 7-89
Educational reference. Not medical advice, diagnosis or treatment.